LEO Pharma has initiated the Phase IIa proof-of-concept DELTA NEXT trial to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle for mild to severe Palmoplantar Pustulosis (PPP). “The DELTA NEXT trial in PPP represents an exciting new chapter in the clinical development journey… Read More
Gilead Sciences and LEO Pharma have agreed a strategic partnership to accelerate the development of LEO Pharma’s small molecule STAT6 programmes for inflammatory diseases. STAT6 is the specific transcription factor required for IL-4 and IL-13 cytokine signalling, which are clinically validated targets for Th2 mediated inflammatory conditions… Read More
The Prescription Medicines Code of Practice Authority (PMCPA), a self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, have opened cases against Leo Pharma, AstraZeneca and Daiichi Sankyo for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. Read More
LEO Pharma and ICON have formed a strategic partnership that will enable LEO to offer clinical trials within medical dermatology that are patient-centric and cost effective. The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges. Read More
